SG/CALL/VERTEX PHARMACEUTICALS/480/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 10:29:40 17/05/2024 pm IST | ||
| 2.67 EUR | +5.12% |
|
| Current month | +86.76% | ||
| 1 month | +53.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 2.67 | +5.12% |
| 16/24/16 | 2.54 | +4.53% |
| 15/24/15 | 2.43 | +9.46% |
| 14/24/14 | 2.22 | -1.77% |
| 13/24/13 | 2.26 | +10.78% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 10:29 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6E0A |
| ISIN | DE000SU6E0A4 |
| Date issued | 29/12/2023 |
| Strike | 480 $ |
| Maturity | 20/12/2024 (217 Days) |
| Parity | 10 : 1 |
| Emission price | 2.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.27 € |
|---|---|
| Lowest since issue | 1.29 € |
| Spread | 0.04 € |
| Spread % | 1.49% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Warrants
- Warrant
